NYSE: STESteris PLC Stock
$200.50-1.49 (-0.74%)
Updated Dec 8, 2023
STE Price
$200.50
Fair Value Price
N/A
Market Cap
$19.81B
52 Week Low
$173.21
52 Week High
$254.00
P/E
36.26x
P/B
3.21x
P/S
4.15x
PEG
1.34x
Dividend Yield
0.99%
Revenue
$5.23B
Earnings
$549.93M
Gross Margin
43.5%
Operating Margin
15.14%
Profit Margin
10.5%
Debt to Equity
0.82
Operating Cash Flow
$849M
Beta
0.87
Next Earnings
Feb 6, 2024
Ex-Dividend
Nov 20, 2023
Next Dividend
Dec 21, 2023
STE Overview
STERIS PLC provides products and services to prevent infections in patients. Products include capital equipment (sterilizers and washers, surgical tables, lights and equipment management systems) and connectivity solutions (operating room integration), consumables (detergents and gastrointestinal endoscopy accessories), and dental instruments. Services offered include equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and off-site reprocessing. STERIS was founded in 1985 and is based in Dublin, IE.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STE ($200.50) is trading above its intrinsic value of $80.67, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STE is poor value based on its earnings relative to its share price (36.26x), compared to the US market average (31.32x)
P/E vs Market Valuation
STE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more STE due diligence checks available for Premium users.
Be the first to know about important STE news, forecast changes, insider trades & much more!
STE News
Valuation
STE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
36.26x
Industry
34.17x
Market
31.32x
STE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
STE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
STE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.21x
Industry
3.55x
STE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STE price to earnings growth (PEG)
For valuing profitable companies with growth potential
STE is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
STE's financial health
Profit margin
Revenue
$1.3B
Net Income
$115.3M
Profit Margin
8.6%
STE's Earnings (EBIT) of $791.52M... subscribe to Premium to read more.
Interest Coverage Financials
STE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.3B
Liabilities
$5.1B
Debt to equity
0.82
STE's short-term assets ($2.17B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STE's long-term liabilities ($4.22B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$146.1M
Investing
-$606.2M
Financing
$470.2M
STE's operating cash flow ($848.60M)... subscribe to Premium to read more.
Debt Coverage Financials
STE vs Medical Device Stocks
Steris Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.